ArticleNPJ precision oncology2024

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors.

Jian Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.